We could get more interim Ph2 injection trial data at anytime. Market appears to be risk on for early stage biotechs with good results. WOW check out NRT today. IMO this will run hard if next trial update is positive as the current market is in party mode. Current SP is below recent 30 cent placement and looks a good buy at this level IMO.